NCT01724606: Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Radiation therapy, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain, Leptomeningeal Disease
Additional Notes: Patient must have planned whole brain radiotherapy (WBRT) based on number (greater than or equal to 3 lesions) and/or size (greater than or equal to 1 cm)
Exclusions: Patients with leptomeningeal metastases unless it is limited to cranial metastasis & not the only metastasis present in the brain – see trial for details; Prior hormonal therapy for metastatic disease is allowed but must be discontinued prior to enrollment; Patients with prior treatment with any agent that targets VEGF, except bevacizumab

Comments are closed.

Up ↑